Journal
EXPERT REVIEW OF VACCINES
Volume 15, Issue 7, Pages 853-862Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2016.1157479
Keywords
human papillomavirus; cervical cancer; oropharyngeal cancer; anogenital cancer; non-melanoma skin cancer; L2; capsid display; multimer; toll-like receptor agonist; adjuvant
Categories
Funding
- NCI NIH HHS [P50 CA098252, R01 CA118790] Funding Source: Medline
- NIAID NIH HHS [U19 AI113187] Funding Source: Medline
Ask authors/readers for more resources
Human papillomavirus (HPV) is a worldwide public health problem, particularly in resource-limited countries. Fifteen high-risk genital HPV types are sexually transmitted and cause 5% of all cancers worldwide, primarily cervical, anogenital and oropharyngeal carcinomas. Skin HPV types are generally associated with benign disease, but a subset is linked to non-melanoma skin cancer. Licensed HPV vaccines based on virus-like particles (VLPs) derived from L1 major capsid antigen of key high risk HPVs are effective at preventing these infections but do not cover cutaneous types and are not therapeutic. Vaccines targeting L2 minor capsid antigen, some using capsid display, adjuvant and fusions with early HPV antigens or Toll-like receptor agonists, are in development to fill these gaps. Progress and challenges with L2-based vaccines are summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available